EGFR and non-small cell lung carcinoma: A retrospective research22 found that patients with EGFR-mutated NSCLC of stage II-III who received immunotherapy combined with chemotherapy as neoadjuvant therapy could achieve an ORR of 63.2%, with an MPR of 42.1% and a PCR of 10.5%.